Dasatinib Monohydrate: Multitargeted Tyrosine Kinase Inhibitor for CML Research

Executive Summary: Dasatinib Monohydrate (BMS-354825) is a clinically validated, multitargeted ATP-competitive tyrosine kinase inhibitor with high potency for ABL, SRC, KIT, and PDGFR kinases (IC₅₀ values: 0.55 nM for Src, 3.0 nM for Bcr-Abl) [APExBIO]. It demonstrates strong in vitro antiproliferative activity against both hematological and solid tumor cell lines, including imatinib-resistant BCR-ABL variants [Telerman et al., 2022]. Dasatinib is approved for treating Philadelphia chromosome-positive leukemias and is a research staple for modeling kinase signaling and drug resistance [APExBIO]. The compound is highly soluble in DMSO (≥25.3 mg/mL), insoluble in water/ethanol, and requires -20°C storage [APExBIO]. Evidence suggests distinct effects among TKIs on neutrophil extracellular trap (NET) formation, underscoring the importance of benchmarked compounds in translational research [Telerman et al., 2022].

Biological Rationale

Chronic myeloid leukemia (CML) is driven by the BCR-ABL1 fusion gene, resulting in constitutive ABL tyrosine kinase activity and uncontrolled myeloid proliferation [Telerman et al., 2022]. Tyrosine kinase inhibitors (TKIs) such as Dasatinib Monohydrate have transformed CML outcomes by specifically targeting the BCR-ABL1 oncoprotein. However, resistance mechanisms, including point mutations in the BCR-ABL kinase domain, necessitate research on next-generation multitargeted inhibitors capable of overcoming these barriers. Dasatinib's broad-spectrum inhibition of ABL, SRC, KIT, and PDGFR kinases allows researchers to dissect complex signaling networks and study the interplay between kinase signaling, leukemic cell survival, and drug resistance [Elevating CML Research Workflows].

Mechanism of Action of Dasatinib Monohydrate

Dasatinib Monohydrate acts as a multitargeted, ATP-competitive inhibitor. Its primary targets include ABL, SRC, KIT, PDGFR, and other tyrosine kinases. Dasatinib binds to the active conformation of the ABL kinase domain, inhibiting phosphorylation events essential for signal transduction and cell proliferation [APExBIO]. The compound exhibits IC₅₀ values of 0.55 nM for Src and 3.0 nM for Bcr-Abl under standard kinase assay conditions (25°C, 10 mM HEPES buffer, pH 7.5) [APExBIO]. Dasatinib is effective against both wild-type and imatinib-resistant BCR-ABL isoforms, including those with the T315I mutation, making it suitable for modeling resistance [Multitargeted Tyrosine Kinase Inhibitor].

Evidence & Benchmarks

• Dasatinib Monohydrate inhibits BCR-ABL and SRC kinases with IC₅₀ values of 3.0 nM and 0.55 nM, respectively, as determined by in vitro kinase assays (APExBIO).
• In CML patient-derived neutrophils, TKIs—including Dasatinib—differentially affect neutrophil extracellular trap (NET) formation, which is implicated in vascular toxicity (Telerman et al., 2022).
• Dasatinib demonstrates broad-spectrum antiproliferative activity against both hematological and solid tumor cell lines in vitro (cell viability measured via MTT assay, 48 h, 37°C, 5% CO₂) (Multitargeted Tyrosine Kinase Inhibitor).
• In mouse models harboring BCR-ABL mutations, Dasatinib treatment (oral, 30 mg/kg/day for 21 days) significantly reduces disease progression and bioluminescent tumor burden (Optimizing CML Research).
• Dasatinib is clinically approved by the FDA since 2006 for treatment of Philadelphia chromosome-positive (Ph+) leukemias, including all phases of CML and Ph+ acute lymphoblastic leukemia (ALL) (APExBIO).

Applications, Limits & Misconceptions

Dasatinib Monohydrate is widely used in research to:

• Model kinase signaling and drug resistance in CML and Ph+ ALL.
• Investigate mechanisms underlying TKI sensitivity and resistance, especially in imatinib-resistant BCR-ABL isoforms.
• Study SRC family kinase signaling in both hematological and solid tumors.
• Dissect the impact of multitargeted kinase inhibition on cell cycle progression and apoptosis.

This article extends findings from Dasatinib Monohydrate: Elevating CML Research Workflows by detailing NET modulation and translational considerations. It also clarifies in vivo efficacy benchmarks discussed in Optimizing CML Research with Multitargeted Inhibition and updates comparative insights from Transforming Tumor Assembloid Research.

Common Pitfalls or Misconceptions

• Dasatinib Monohydrate is not effective against T315I-mutant BCR-ABL at clinical concentrations; other inhibitors such as ponatinib are required for full suppression [Telerman et al., 2022].
• Solubility constraints: Dasatinib is insoluble in water and ethanol; DMSO (≥25.3 mg/mL) is required for stock preparation [APExBIO].
• Short-term solution stability: Solutions are unstable at room temperature and should be used immediately or stored at -20°C for short durations [APExBIO].
• Overgeneralization: Not all multitargeted TKIs exert the same effects on NET formation or vascular toxicity; effects are kinase- and context-dependent [Telerman et al., 2022].
• Not a pan-kinase inhibitor: Dasatinib targets a defined subset of tyrosine kinases; serine/threonine kinases are largely unaffected [APExBIO].

Workflow Integration & Parameters

• Solubility and Storage: Prepare stocks in DMSO (≥25.3 mg/mL), store at -20°C, avoid freeze-thaw cycles. Use freshly prepared solutions for optimal activity [APExBIO].
• Concentration Ranges: In vitro assays typically use 1–100 nM for kinase inhibition; adjust based on cell line and endpoint.
• Controls: Include vehicle (DMSO) and reference TKI controls for benchmarking.
• Readouts: Monitor cell proliferation, apoptosis, kinase phosphorylation (e.g., Western blot for p-BCR-ABL), and NET formation as appropriate.
• Compliance: For translational studies, note clinical dosing equivalence: Dasatinib is FDA-approved for Ph+ leukemias at oral doses of 100–140 mg/day [APExBIO].

For advanced workflow strategies and troubleshooting, see Multitargeted Tyrosine Kinase Inhibitor, which this article updates with recent data on NET modulation and kinase selectivity.

Conclusion & Outlook

Dasatinib Monohydrate (BMS-354825) from APExBIO is a benchmark multitargeted tyrosine kinase inhibitor for CML and kinase signaling research. Its efficacy in imatinib-resistant models, broad kinase inhibition, and well-characterized pharmacology support translational and mechanistic studies. Researchers should be aware of distinct NET-modulatory effects and context-specific limitations. Ongoing studies into TKI-induced vascular toxicity and resistance mechanisms will further define its optimal deployment. For detailed specifications and ordering, visit the Dasatinib Monohydrate product page.